Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin

British Journal of Cancer

Volumn 73, Issue 2, 1996, Pages 217-221

  Matsui, K ^a   Fukuoka, M ^a   Takada, M ^a   Kusunoki, Y ^a   Yana, T ^a   Tamura, K ^a   Yoshida, T ^a   Iida, K ^a   Hirashima, T ^a   Tsukada, H ^a   Ushijima, S ^a   Miyawaki, H ^a   Masuda, N ^a  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

Author keywords

Cisplatin; Delayed emesis; Dexamethasone; Granisetron; Prochlorperazine

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; DEXAMETHASONE; GRANISETRON; PROCHLORPERAZINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MALE; MORBIDITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VOMITING;

EID: 9044231764     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.38     Document Type: Article

References (22)

1. CHEVALLIER B ON BEHALF OF THE GRANISETRON STUDY GROUP. (1993). The control of acute cisplatin-induced emesis - a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Br. J. Cancer, 68, 176-180.
2. CUNNINGHAM D, POPLE A, FORD HT, HAUTHORN J, GAZET J-C, CHALLONER T AND COOMBES RC. (1987). Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet, 1, 1461-1463.
3. GANDARA DR, HARVEY WH, MONAGHAN GG, PEREZ EA, STOKES C, BRYSON JC, FINN AL AND HESKETH PJ. (1992). The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin. Oncol., 19, (suppl. 10), 67-71.
4. GRALLA RJ, ITRI LM, PISKO SE, SQUILLANTE AE, KELSEN DP, BRAUN DW JR, BORDIN LA, BRAUN TJ AND YOUNG CW. (1981). Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N. Engl. J. Med., 305, 905-909.
5. HAINSWORTH JD AND HESKETH PJ. (1992). Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results. Semin. Oncol., 19, (suppl. 15), 14-19.
6. 3 receptors. Cancer Chemother. Pharmacol., 24, 307-310.
7. HERRSTEDT J, SIGSGAARD T, BOESGAARD M, JENSEN TP AND DOMBERNOUSKY P. (1993). Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N. Engl. J. Med., 328, 1076-1080.
8. ITALIAN GROUP FOR ANTIEMETIC RESEARCH. (1993). Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. J. Clin. Oncol., 11, 2396-2404.
9. ITALIAN GROUP FOR ANTIEMETIC RESEARCH. (1994). Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Ann. Oncol., 5, 585-589.
10. JANTUNEN IT, MUHONEN TT, KATAJA VV, FLANDER MK AND TEERENHOVI L. (1993). 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy a randomized study. Eur. J. Cancer., 29A, 1669-1672.
11. JOSS RA, DOTT CS. ON BEHALF OF THE GRANISETRON STUDY GROUP. (1993). Clinical studies with granisetron, a new 5-HT3 receptor antagonist for the treatment of cancer chemotherapy-induced emesis. Eur. J. Cancer, 29A, (suppl. 1), S22-S29.
12. KAIZER L, WARR D, HOSKINS P, LATREILLE J, LOFTERS W, YAU J, PALMER M, ZEE B, LEVY M AND PATER J. (1994). Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 12, 1050-1057.
13. 3 antagonist? Lancet, 340, 1107-1108.
14. KRIS MG, TYSON LB, GRALLA RJ, CLARK RA, ALLEN JC AND REILLY LK. (1983). Extrapyramidal reactions with high-dose metoclopramide. N. Engl. J. Med., 309, 433.
15. KRIS MG, GRALLA RJ, TYSON LB, CLARK RA, KELSEN DP, REILLY LK, GROSHEN S, BOSL GJ AND KALMAN LA. (1985a). Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine; results of consecutive trials in 255 patients. Cancer, 55, 527-534.
16. KRIS MG, GRALLA RJ, CLARK RA, TYSON LB, O'CONNELL JP, WERTHEIM MS AND KELSEN DP. (1985b). Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J. Clin. Oncol., 3, 1379-1384.
17. KRIS MG, GRALLA RJ, TYSON LB, CLARK RA, CIRRINCIONE C AND GROSHEN S. (1989). Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J. Clin. Oncol., 7, 108-114.
18. LOUVET C, LORANGE A, LETENDRE F, BEAULIEU R, PRETTY HM, COURCHESNE Y, NEEMEH JA, MONTE M AND LATREILLE J. (1991). Acute and delayed emesis after cisplatin-based regimen: description and prevention. Oncology, 48, 392-396.
19. MORENO I, ROSELL R, ABAD A, BARNADAS A, CALRES J, RIBELLES N, SOLANO V AND FONT R. (1992). A comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur. J. Cancer, 28A, 1344-1347.
20. ROILA F, TONATO M, COGNETTI F, CORTESI E, FAVALLI G, MARANGOLO M, AMADORI D, BELLA MA, GRAMAZIO V, DONATI D, BALLATORI E AND DEL FAVERO A. (1991). Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J. Clin. Oncol., 9, 675-678.
21. VON HOFF DD, SCHILSKY R, REICHERT CM, REDDICK RL, ROZENCWEIG M, YOUNG RC AND MUGGIA FM (1979). Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat. Rep., 63, 1527-1531.
22. WORLD HEALTH ORGANIZATION. (1979). WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. World Health Organization: Geneva.